Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study
Open accessAbstract
Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. Large screening of different biological compartments, such as the proteome, by means of high throughput techniques may greatly help scientists to find such markers. The present retrospective multicentric study included 268 node-negative breast cancer patients. We used a proteomic approach of SELDI-TOF-MS screening to identify differentially expressed cytosolic proteins with prognostic impact. The screening cohort was composed of 198 patients. Seventy supplementary patients were included for validation. Immunohistochemistry (IHC) and immunoassay (IA) were run to confirm the prognostic role of the marker identified by SELDI-TOF-MS screening. IHC was also used to explore links between selected marker and epithelial-mesenchymal transition (EMT)-like, proliferation and macrophage markers. Ferritin light chain (FTL) was identified as an independent prognostic marker (HR = 1.30-95% CI: 1.10-1.50, p = 0.001). Validation step by means of IHC and IA confirmed the prognostic value of FTL level. CD68 IHC showed that FTL was stored in tumor-associated macrophages (TAM), which exhibit an M2-like phenotype. We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Expression of FT is considered a prognostic marker for some cancer subtypes such as squamous cell carcinoma or breast cancer.
“For this reason, the expression of FT is considered a prognostic marker for some cancer subtypes such as squamous cell carcinoma or breast cancer [27,36,37].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [27]
Ferritin expression is mainly in the stromal compartment of tumor tissue.
“These findings were corroborated by a variety of studies showing ferritin expression mainly in the stromal compartment of tumor tissue [26,27].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 45 · Cited by 85
Research works printed but not linked: 3
- Adjuvant therapy for breast cancer. NIH Consensus Statement 2000;17:1-35.
- V C 2011 UICC 10970215, 2012, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ijc.26397, Wiley Online Library on [12/07/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
- Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R, Je ´ze ´quel P. Comparative prognostic value of UBE2C and Ki-67 immunohistochemistry staining in node-positive breast cancer. Br J Cancer 2009;101:166-73.
- Authors
- Jézéquel, P., Campion, L., Spyratos, F., Loussouarn, D., Campone, M., Guérin‐Charbonnel, C., Joalland, M., André, J., Descotes, F., Grenot, C., Roy, P., Carlioz, A., Martin, P., Chassevent, A., Jourdan, M., & Ricolleau, G.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- Hôpital René Huguenin (FR)
- Hospices Civils de Lyon (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Hôpital Bretonneau (FR)
- Corresponding author
- Jézéquel, Pascal
- ORCID
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-10-20
- Volume
- 131
- Issue
- 2
- Pages
- 426-437
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2044798556
- Cited by
- 85
- References
- 45
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 7 · 2020: 13 · 2019: 6 · 2018: 7 · 2017: 9 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 11 · 2012: 1
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Institut National Du Cancer
- Hospices Civils de Lyon
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- ferritin light chain, tumor-associated macrophages, node-negative breast cancer, prognostic factors, CD68, M2 macrophage phenotype, epithelial-mesenchymal transition, tumor cell proliferation, cytosolic proteins
- MeSH terms
- CD68 Molecule, Adult, Aged, Apoferritins, Breast Neoplasms, Cytosol, Female, Humans, Macrophages, Middle Aged, Prognosis, Biomarkers, Tumor, Antigens, Differentiation, Myelomonocytic, Cohort Studies, Antigens, CD, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Proteomics, Cell Proliferation, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
